RxLedger

Medicare Part D drugs (A–Z)

This is the index of the 350 highest-spend Medicare Part D drugs, out of about 3,598 drugs in the CMS dataset (data year 2023). Each has its own page with total spending, spending per dosage unit, per claim and per beneficiary, claims, beneficiaries, manufacturer and year-over-year change. The biggest is Eliquis (Apixaban) at $18,273,451,967. Use the top-50 table or jump to a letter below. These are aggregate program figures, not the price you pay.

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

Top 50 drugs by total Part D spending (2023)

RankDrugTotal spendPer dosage unitBeneficiaries
#1Eliquis (Apixaban)$18,273,451,967$9.743,927,848
#2Ozempic (Semaglutide)$9,194,048,435$355.901,464,468
#3Jardiance (Empagliflozin)$8,839,935,063$20.321,882,768
#4Trulicity (Dulaglutide)$7,363,856,224$483.21938,731
#5Xarelto (Rivaroxaban)$6,309,246,823$18.231,324,165
#6Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter)$4,455,884,010$11.181,050,583
#7Humira(Cf) Pen (Adalimumab)$4,419,828,188$3,750.0661,474
#8Farxiga (Dapagliflozin Propanediol)$4,342,182,307$19.55993,909
#9Januvia (Sitagliptin Phosphate)$4,090,836,821$18.88843,391
#10Revlimid (Lenalidomide)$3,859,804,789$878.2136,967
#11Entresto (Sacubitril/Valsartan)$3,430,441,590$11.64663,587
#12Lantus Solostar (Insulin Glargine,Hum.Rec.Anlog)$3,157,233,282$30.281,198,294
#13Biktarvy (Bictegrav/Emtricit/Tenofov Ala)$3,152,256,269$133.1383,843
#14Stelara* (Ustekinumab)$2,987,778,600$26,818.0322,930
#15Xtandi (Enzalutamide)$2,601,510,278$146.1328,658
#16Myrbetriq (Mirabegron)$2,510,288,600$15.43769,978
#17Imbruvica (Ibrutinib)$2,371,893,292$486.6317,100
#18Mounjaro (Tirzepatide)$2,361,384,157$539.82370,203
#19Enbrel Sureclick (Etanercept)$2,054,858,499$1,812.3634,287
#20Ibrance (Palbociclib)$2,020,903,604$753.0216,015
#21Symbicort (Budesonide/Formoterol Fumarate)$2,004,295,918$38.98984,400
#22Jakafi (Ruxolitinib Phosphate)$1,940,765,069$297.8814,041
#23Novolog Flexpen (Insulin Aspart)$1,875,605,627$38.82588,526
#24Ofev (Nintedanib Esylate)$1,837,061,150$220.8420,444
#25Linzess (Linaclotide)$1,825,245,843$18.14565,088
#26Invega Sustenna (Paliperidone Palmitate)$1,821,418,393$2,343.5370,988
#27Pomalyst (Pomalidomide)$1,709,288,465$1,088.7612,739
#28Ingrezza (Valbenazine Tosylate)$1,705,132,723$267.5729,191
#29Lenalidomide$1,681,292,157$682.2920,403
#30Rybelsus (Semaglutide)$1,665,906,943$32.41285,693
#31Restasis (Cyclosporine)$1,501,664,198$11.33492,479
#32Creon (Lipase/Protease/Amylase)$1,466,866,603$8.87185,325
#33Arexvy (Rsvpref3 Antigen/As01e/PF)$1,387,933,256$315.814,390,151
#34Breo Ellipta (Fluticasone/Vilanterol)$1,373,600,714$6.94556,799
#35Vyndamax (Tafamidis)$1,349,659,508$735.477,589
#36Tradjenta (Linagliptin)$1,293,567,778$18.04286,808
#37Calquence (Acalabrutinib Maleate)$1,286,819,830$255.9612,390
#38Tagrisso (Osimertinib Mesylate)$1,231,962,204$569.459,387
#39Shingrix (Varicella-Zoster Ge/As01b/PF)$1,211,171,028$212.263,894,337
#40Humalog Kwikpen U-100 (Insulin Lispro)$1,208,385,334$35.80418,431
#41Skyrizi Pen (Risankizumab-Rzaa)$1,189,321,833$20,593.6018,206
#42Austedo (Deutetrabenazine)$1,123,439,045$103.6118,283
#43Cabometyx (Cabozantinib S-Malate)$1,109,315,042$878.248,210
#44Repatha Sureclick (Evolocumab)$1,092,210,722$286.44229,666
#45Xifaxan (Rifaximin)$1,090,110,101$54.9396,011
#46Dupixent Pen (Dupilumab)$1,081,417,351$951.7241,263
#47Erleada (Apalutamide)$1,057,789,083$156.5811,077
#48Tresiba Flextouch U-200 (Insulin Degludec)$1,047,670,731$71.71197,096
#49Levemir Flexpen (Insulin Detemir)$1,025,556,477$32.59346,204
#50Opsumit (Macitentan)$1,018,837,123$424.669,031

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

See all 350 ranked by spend →

All 350 drugs A–Z

Jump to: A B C D E F G H I J K L M N O P Q R S T U V W X Z

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Z

Frequently asked questions

How many drugs are in the Medicare Part D spending data?

The CMS Medicare Part D Spending by Drug dataset covers about 3,598 drugs for data year 2023. This site publishes a full detail page for the 350 highest-spend drugs (which account for the large majority of total program spending); the long tail of lower-spend drugs is listed in the ranking tables and will be expanded in later waves.

How are the drugs sorted?

The headline table is sorted by total Medicare Part D spending in 2023 (highest first). The A-Z index below lists every published drug alphabetically by brand name so you can jump straight to one.

More ways to explore

Data: CMS Medicare Part D Spending by Drug (data year 2023), U.S. public domain. Aggregate program spending, not the price you pay. Data as of June 2026.

Last updated: 2026-06-21